SOUTH SAN FRANCISCO, Calif., April 14, 2020 CareDx, Inc.(Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today a biopharma research partnership for AlloCell. AlloCell is a surveillance solution for patients who have received engineered-cell transplants for allogeneic cell therapy.
SUZHOU, Chinaand SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd.
SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biology, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19). The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit.
EL SEGUNDO, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., clinical-stage immunotherapy companies within the NantWorks family of companies, today announced they are in active discussions with the U.S
The Mesenchymal Stem Cells Market is expected to have a highly positive outlook for the next eight years 2019-2026. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to drivers, opportunities, pricing details and latest trends in the industry
Orgenesis to Acquire Tamir Biotechnology's Assets for $19 Million Orgenesis Inc. (ORGS) reported that it has signed a deal with Tamir Biotechnology Inc., under which the former will acquire the assets of the latter, including its broad spectrum antiviral platform ranpirnase. The deal is cash- and stock-based and is expected to be worth nearly $19 million.
During the in vitro culture of cells, small molecules are often used to manipulate signaling pathways. These signaling pathways are important targets for small molecules in the culture of stem cells that control cell proliferation and differentiation
During the in vitro culture of cells, small molecules are often used to manipulate signaling pathways.
TOKYO, April 14, 2020 /PRNewswire/ -- HEALIOS K.K. ("Healios") continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051*1, a somatic stem cell regenerative medicine therapy, for pneumonia-induced Acute Respiratory Distress Syndrome (ARDS) *2
TOKYO, April 14, 2020 /PRNewswire/ -- HEALIOS K.K. ("Healios") continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051*1, a somatic stem cell regenerative medicine therapy, for pneumonia-induced Acute Respiratory Distress Syndrome (ARDS) *2. As announced on March 26, 2020, Healios has been in discussions with medical specialists and the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the inclusion of pneumonia-induced ARDS patients infected with the novel coronavirus, "We hereby inform you that we have decided to make a protocol change to the ONE-BRIDGE study to include these patients in the ongoing trial
Recent Comments